{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:12:01Z","timestamp":1787969521327,"version":"build-2784847793"},"reference-count":48,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Haemoglobinopathies, including \u03b2-thalassaemia and sickle cell disease (SCD), are among the most common monogenic disorders worldwide and remain major causes of morbidity and early mortality. Historically, management of these life-altering diseases has relied on supportive treatment and symptom management and, although these treatments reduce symptoms and ease disease burden, they do not correct the underlying genetic defect. Allogenic haematopoietic stem cell transplantation (HSCT) has been the only established curative option; however, it comes with substantial risks that significantly restrict its applicability. Over the past two decades, haematopoietic stem cell (HSC) gene therapy for haemoglobinopathies has rapidly progressed from experimental proof-of-concept to approved therapies. Lentiviral gene addition approaches have demonstrated durable expression of functional \u03b2-like globin transgenes, achieving transfusion independence in \u03b2-thalassaemia patients and significant reductions in vaso-occlusive events in SCD patients. Alternative therapeutic approaches to promote HbF expression have proved to be highly successful. Gene silencing strategies targeting BCL11A have been successful clinically and, more recently, gene editing technologies such as CRISPR\/Cas9 have enabled precise disruption of regulatory elements controlling \u03b3-globin repression, leading to the approval of the first CRISPR-based therapy for SCD and \u03b2-thalassaemia. Emerging base editing technologies promise even more precise genetic modification and are advancing through clinical evaluation. Despite these advances, access to gene therapy remains restricted due to the need for highly specialised manufacturing, toxic myeloablative conditioning regimens, and high treatment costs. Ongoing improvements and adaptations in these areas are essential to ensure that gene therapies fulfil their potential as accessible, curative treatments for patients suffering from haemoglobinopathies worldwide.<\/jats:p>","DOI":"10.3390\/hematolrep18010004","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:25:51Z","timestamp":1766989551000},"page":"4","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Gene Therapy for Inherited Haemoglobinopathies"],"prefix":"10.3390","volume":"18","author":[{"given":"Anna B.","family":"Gaspar","sequence":"first","affiliation":[{"name":"Kings College Hospital Foundation Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-7213","authenticated-orcid":false,"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK"},{"name":"Orchard Therapeutics, London W6 8PW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1203\/00006450-200204000-00003","article-title":"Regulation of the globin genes","volume":"51","author":"Cao","year":"2002","journal-title":"Pediatr. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-031-62731-6_9","article-title":"Transcriptional Repressor BCL11A in Erythroid Cells","volume":"1459","author":"Zheng","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/20009666.2018.1536241","article-title":"Blessing in disguise; A case of Hereditary Persistence of Fetal Hemoglobin","volume":"8","author":"Shaukat","year":"2018","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Inusa, B.P.D., Hsu, L.L., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K.A., and Atoyebi, W. (2019). Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. Int. J. Neonatal Screen., 5.","DOI":"10.3390\/ijns5020020"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2010-11-316893","article-title":"Transcriptional regulation of fetal to adult hemoglobin switching: New therapeutic opportunities","volume":"117","author":"Wilber","year":"2011","journal-title":"Blood"},{"key":"ref_9","unstructured":"Bluebird Bio, Inc. (2025, September 30). Bluebird Bio Announces FDA Approval of ZYNTEGLO\u00ae, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions. Available online: https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy."},{"key":"ref_10","unstructured":"Bluebird Bio, Inc. (2025, September 30). Bluebird Bio Announces FDA Approval of LYFGENIATM (Lovotibeglogene Autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events. Available online: https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-announces-fda-approval-lyfgeniatm-lovotibeglogene."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood-2021-147469","article-title":"Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1\/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning","volume":"138","author":"Grimley","year":"2021","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease","volume":"384","author":"Esrick","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24298","DOI":"10.1038\/s41598-024-74716-7","article-title":"Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease","volume":"14","author":"Lessard","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2024-200875","article-title":"Impact of BEAM-101 Treatment on Red Blood Cell Hemoglobin Expression, Rheology and Sickling Properties: Initial Data from the BEACON Phase 1\/2 Study of Autologous CD34+ Base Edited Hematopoietic Stem Cells in Sickle Cell Disease","volume":"144","author":"Chockalingam","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1182\/blood-2021-150922","article-title":"Conversion of HbS to Hb G-Makassar By Adenine Base Editing Is Compatible with Normal Hemoglobin Function","volume":"138","author":"Chu","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2022016629","article-title":"Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) \u03b2-thalassemia mutation","volume":"141","author":"Hardouin","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102183","DOI":"10.1016\/j.omtn.2024.102183","article-title":"Context base editing for splice correction of IVSI-110 \u03b2-thalassemia","volume":"35","author":"Naiisseh","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/hum.2016.007","article-title":"Gene Therapy of the \u03b2-Hemoglobinopathies by Lentiviral Transfer of the \u03b2(A(T87Q))-Globin Gene","volume":"27","author":"Negre","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.omtm.2020.04.013","article-title":"\u03b2T87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells","volume":"17","author":"Demirci","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Payen","year":"2010","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene Therapy in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2018-99-113480","article-title":"Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study","volume":"132","author":"Tisdale","year":"2018","journal-title":"Blood"},{"key":"ref_26","first-page":"355","article-title":"Gene therapy for beta thalassemia: Preliminary results from the phase I\/II tiget-bthal trial of autologous hemato- poietic stem cells genetically modified with GLOBE lentiviral vector","volume":"130","author":"Marktel","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood.V95.10.3242","article-title":"Locus control region activity by 5\u2019HS3 requires a functional interaction with beta-globin gene regulatory elements: Expression of novel beta\/gamma-globin hybrid transgenes","volume":"95","author":"Rubin","year":"2000","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2009-01-201863","article-title":"A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: Critical determinants for successful correction","volume":"114","author":"Perumbeti","year":"2009","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14055","DOI":"10.1038\/mtm.2014.55","article-title":"Pigtailed macaques as a model to study long- term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies","volume":"1","author":"Kiem","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.omtm.2020.03.015","article-title":"Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy","volume":"17","author":"Brendel","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"23549","DOI":"10.1038\/srep23549","article-title":"Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing","volume":"6","author":"Miyaoka","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-05-1681","article-title":"Persistent gamma-globin expression in adult transgenic mice is mediated by HPFH-2, HPFH-3, and HPFH-6 breakpoint sequences","volume":"102","author":"Katsantoni","year":"2003","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1534\/genetics.111.131433","article-title":"Genome engineering with zinc-finger nucleases","volume":"188","author":"Carroll","year":"2011","journal-title":"Genetics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41588-023-01434-7","article-title":"Potent and uniform fetal hemoglobin induction via base editing","volume":"55","author":"Mayuranathan","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.stem.2023.10.007","article-title":"Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs","volume":"30","author":"Han","year":"2023","journal-title":"Cell Stem Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: Time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2019-126239","article-title":"Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency","volume":"134","author":"Agarwal","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1016\/j.ymthe.2025.07.012","article-title":"HSC engraftment is enhanced by combining mobilization with anti-C-Kit and Anti-CD47-based conditioning in hematopoietic transplant","volume":"33","author":"Segovia","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: A systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"Thomson","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1056\/NEJMoa2405734","article-title":"CRISPR-based therapy for hereditary angioedema","volume":"392","author":"Cohn","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_47","unstructured":"(2025, September 30). A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients with Refractory Hyperlipidemia. ClinicalTrials:NCT06451770, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06451770."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:16:49Z","timestamp":1767071809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["hematolrep18010004"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18010004","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]}}}